Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| A5991081 |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
To compare recurrence free survival between two treatment groups (5 years with exemestane vs 2.5 to 3 years tamoxifen followed by 2 to 2.5 years of exemestane for a total duration of 5 years)
This Pfizer sponsored trial is part of an international collaboration of investigators conducting 7 similar yet independent studies in 9 countries. This study is designed to be part of the larger TEAM trial where the data from these 7 studies will be combined. A pre-specified analysis of the pooled data will be conducted. Link to TEAM Trial [971-ONC-0028-081/A5991026] Study Results: http://clinicaltrials.gov/ct2/show/results/NCT00036270?term=971-ONC-0028-081\&rank=1
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| A | Experimental |
| |
| B | Active Comparator |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| exemestane | Drug | On tablet of 25 mg per day during 5 years |
|
|
| Measure | Description | Time Frame |
|---|---|---|
| To compare recurrence free survival between two treatment groups. | 2.75 years and 5 years |
| Measure | Description | Time Frame |
|---|---|---|
| The quality of life of patients treated with exemestane to that of patients treated with tamoxifen | Every 3 months during first year then every 6 months for 4 years | |
| Overall survival between the 2 treatment groups | Every 3 months during first year then every 6 months for 4 years |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Pfizer CT.gov Call Center | Pfizer | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Pfizer Investigational Site | Marseille | Be1 01971 | 13285 | France | ||
| Pfizer Investigational Site |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 41980703 | Derived | Pilgram L, Yang K, Beltran-Bless AA, Pond GR, Vandermeer L, Hilton J, Savard MF, LeBlanc A, Shepherd L, Chen B, Bartlett JM, Taylor KJ, Bayani J, Barker S, Spears M, van der Velde CJ, Meershoek-Klein Kranenbarg E, Dirix L, Mallon E, Hasenburg A, Markopoulos C, Juwara L, Dankar FK, Clemons M, El Emam K. Transfer Learning and Machine Learning for Training Five-Year Survival Prognostic Models in Early Breast Cancer: Development and Validation Study. J Med Internet Res. 2026 Apr 14;28:e88665. doi: 10.2196/88665. | |
| 41642493 |
| Label | URL |
|---|---|
| To obtain contact information for a study center near you, click here. | View source |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| tamoxifen | Drug | Two tablets of tamoxifen 10 mg per day during 2.5 to 3 years followed by one tablet of exemestane 25 mg per day during 2 to 2.5 years for a total duration of 5 years of treatment |
|
|
| Incidence of a second breast cancer (contralateral) between the 2 treatment groups | Every 3 months during first year then every 6 months for 4 years |
| General tolerance in the short- and long-term between the 2 treatment groups | Every 3 months during first year then every 6 months dor 4 years |
| Compiègne |
| Be1 02256 |
| 60200 |
| France |
| Pfizer Investigational Site | Rennes | Be1 03677 | 35033 | France |
| Pfizer Investigational Site | Brest | Be1 04292 | 29609 | France |
| Pfizer Investigational Site | Aix-en-Provence | 13616 | France |
| Pfizer Investigational Site | Amiens | 80000 | France |
| Pfizer Investigational Site | Annecy | 74011 | France |
| Pfizer Investigational Site | Avignon | 84082 | France |
| Pfizer Investigational Site | Bayonne | 64100 | France |
| Pfizer Investigational Site | Blois | 41000 | France |
| Pfizer Investigational Site | Bordeaux | 33000 | France |
| Pfizer Investigational Site | Bordeaux | 33076 | France |
| Pfizer Investigational Site | Brest | 29283 | France |
| Pfizer Investigational Site | Cagne Sur Mer | 06805 | France |
| Pfizer Investigational Site | Chalon-sur-Saône | 71100 | France |
| Pfizer Investigational Site | Chaumont | 52000 | France |
| Pfizer Investigational Site | Croix | 59170 | France |
| Pfizer Investigational Site | Dijon | 21000 | France |
| Pfizer Investigational Site | Douai | 59500 | France |
| Pfizer Investigational Site | Draguignan | 83007 | France |
| Pfizer Investigational Site | Dunkirk | 59240 | France |
| Pfizer Investigational Site | Évreux | 27000 | France |
| Pfizer Investigational Site | Hyres | 83400 | France |
| Pfizer Investigational Site | L'Union | 31240 | France |
| Pfizer Investigational Site | Le Havre | 76600 | France |
| Pfizer Investigational Site | Lille | 59000 | France |
| Pfizer Investigational Site | Lorient | France |
| Pfizer Investigational Site | Lyon | 69008 | France |
| Pfizer Investigational Site | Mareuil-lès-Meaux | France |
| Pfizer Investigational Site | Marseille | 13006 | France |
| Pfizer Investigational Site | Marseille | 13009 | France |
| Pfizer Investigational Site | Marseille | 13012 | France |
| Pfizer Investigational Site | Metz | 57072 | France |
| Pfizer Investigational Site | Montauban | 82017 | France |
| Pfizer Investigational Site | Montbéliard | 25200 | France |
| Pfizer Investigational Site | Montélimar | 26026 | France |
| Pfizer Investigational Site | Montpellier | 34059 | France |
| Pfizer Investigational Site | Mougins | 06250 | France |
| Pfizer Investigational Site | Nancy | 54000 | France |
| Pfizer Investigational Site | Nantes | 44202 | France |
| Pfizer Investigational Site | Neuilly | 92200 | France |
| Pfizer Investigational Site | Nice | 06050 | France |
| Pfizer Investigational Site | Nîmes | 30900 | France |
| Pfizer Investigational Site | Paris | 75248 | France |
| Pfizer Investigational Site | Pessac | 33600 | France |
| Pfizer Investigational Site | Quincy-sous-Sénart | 91480 | France |
| Pfizer Investigational Site | Reims | 51100 | France |
| Pfizer Investigational Site | Ris-Orangis | 91130 | France |
| Pfizer Investigational Site | Saint-Brieuc | 22105 | France |
| Pfizer Investigational Site | Saint-Cloud | 92210 | France |
| Pfizer Investigational Site | Saint-Herblain | 44805 | France |
| Pfizer Investigational Site | Saint-Nazaire | 44600 | France |
| Pfizer Investigational Site | Strasbourg | 67000 | France |
| Pfizer Investigational Site | Toulon | 83056 | France |
| Pfizer Investigational Site | Toulouse | 31000 | France |
| Pfizer Investigational Site | Toulouse | 31400 | France |
| Pfizer Investigational Site | Vandœuvre-lès-Nancy | 54511 | France |
| Pfizer Investigational Site | Vannes | 56001 | France |
| Pfizer Investigational Site | Vannes | 58000 | France |
| Derived |
| Leblanc A, Beltran-Bless AA, Pond GR, El Emam K, Juwara L, Clemons L, Bayani J, Pilgram L, Pharoah P, Mallon E, Taylor KJ, Markopoulos C, Dirix L, Vandermeer L, Hilton J, Savard MF, Bartlett JMS, Clemons M. Prognostic and predictive performance of PREDICT 2.1, PREDICT v3, and RSClin in node-negative early breast cancer: a TEAM pathology substudy. Breast Cancer Res Treat. 2026 Feb 5;215(3):74. doi: 10.1007/s10549-026-07909-5. |
| 40633461 | Derived | Beltran-Bless AA, Pond GR, Bayani J, Barker SL, Spears M, Mallon E, Taylor KJ, Hasenburg A, Markopoulos C, Dirix L, Meershoek-Klein Kranenbarg E, van de Velde CJH, Rea DW, Vandermeer L, Hilton J, Bartlett JMS, Clemons M. Does RSClin provide additional information over classic clinico-pathologic scores (PREDICT 2.1, INFLUENCE 2.0, CTS5)? Breast. 2025 Oct;83:104528. doi: 10.1016/j.breast.2025.104528. Epub 2025 Jul 4. |
| 35100692 | Derived | Bayani J, Kornaga EN, Crozier C, Jang GH, Bathurst L, Kalatskaya I, Trinh QM, Yao CQ, Livingstone J, Boutros PC, Spears M, McPherson JD, Stein LD, Rea D, Bartlett JMS. Identification of Distinct Prognostic Groups: Implications for Patient Selection to Targeted Therapies Among Anti-Endocrine Therapy-Resistant Early Breast Cancers. JCO Precis Oncol. 2019 Dec;3:1-13. doi: 10.1200/PO.18.00373. |
| 29885375 | Derived | Derks MGM, Bastiaannet E, van de Water W, de Glas NA, Seynaeve C, Putter H, Nortier JWR, Rea D, Hasenburg A, Markopoulos C, Dirix LY, Portielje JEA, van de Velde CJH, Liefers GJ. Impact of age on breast cancer mortality and competing causes of death at 10 years follow-up in the adjuvant TEAM trial. Eur J Cancer. 2018 Aug;99:1-8. doi: 10.1016/j.ejca.2018.04.009. Epub 2018 Jun 6. |
| 28732650 | Derived | Derks MGM, Blok EJ, Seynaeve C, Nortier JWR, Kranenbarg EM, Liefers GJ, Putter H, Kroep JR, Rea D, Hasenburg A, Markopoulos C, Paridaens R, Smeets JBE, Dirix LY, van de Velde CJH. Adjuvant tamoxifen and exemestane in women with postmenopausal early breast cancer (TEAM): 10-year follow-up of a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 2017 Sep;18(9):1211-1220. doi: 10.1016/S1470-2045(17)30419-9. Epub 2017 Jul 18. |
| 28659176 | Derived | Kalatskaya I, Trinh QM, Spears M, McPherson JD, Bartlett JMS, Stein L. ISOWN: accurate somatic mutation identification in the absence of normal tissue controls. Genome Med. 2017 Jun 29;9(1):59. doi: 10.1186/s13073-017-0446-9. |
| 24091623 | Derived | Bartlett JM, Brookes CL, Piper T, van de Velde CJ, Stocken D, Lyttle N, Hasenburg A, Quintayo MA, Kieback DG, Putter H, Markopoulos C, Kranenbarg EM, Mallon EA, Dirix LY, Seynaeve C, Rea DW. Do type 1 receptor tyrosine kinases inform treatment choice? A prospectively planned analysis of the TEAM trial. Br J Cancer. 2013 Oct 29;109(9):2453-61. doi: 10.1038/bjc.2013.609. Epub 2013 Oct 3. |
| 21247627 | Derived | van de Velde CJ, Rea D, Seynaeve C, Putter H, Hasenburg A, Vannetzel JM, Paridaens R, Markopoulos C, Hozumi Y, Hille ET, Kieback DG, Asmar L, Smeets J, Nortier JW, Hadji P, Bartlett JM, Jones SE. Adjuvant tamoxifen and exemestane in early breast cancer (TEAM): a randomised phase 3 trial. Lancet. 2011 Jan 22;377(9762):321-31. doi: 10.1016/S0140-6736(10)62312-4. |
| Link to TEAM Trial \[971-ONC-0028-081/A5991026\] Study Results | View source |
| ID | Term |
|---|---|
| D001943 | Breast Neoplasms |
| ID | Term |
|---|---|
| D009371 | Neoplasms by Site |
| D009369 | Neoplasms |
| D001941 | Breast Diseases |
| D012871 | Skin Diseases |
| D017437 | Skin and Connective Tissue Diseases |
Not provided
Not provided
| ID | Term |
|---|---|
| C056516 | exemestane |
| D013629 | Tamoxifen |
| ID | Term |
|---|---|
| D013267 | Stilbenes |
| D001597 | Benzylidene Compounds |
| D001555 | Benzene Derivatives |
| D006841 | Hydrocarbons, Aromatic |
| D006844 | Hydrocarbons, Cyclic |
| D006838 | Hydrocarbons |
| D009930 | Organic Chemicals |
Not provided
Not provided